These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 33770020)

  • 1. Health Care Costs of Target Attainment for Beta-Lactam Antibiotics in Critically Ill Patients: A Retrospective Analysis of the EXPAT Study.
    Ewoldt TMJ; Abdulla A; Hunfeld NGM; Muller AE; Gommers D; Polinder S; Koch BCP; Endeman H
    Ther Drug Monit; 2022 Feb; 44(1):224-229. PubMed ID: 33770020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Failure of target attainment of beta-lactam antibiotics in critically ill patients and associated risk factors: a two-center prospective study (EXPAT).
    Abdulla A; Dijkstra A; Hunfeld NGM; Endeman H; Bahmany S; Ewoldt TMJ; Muller AE; van Gelder T; Gommers D; Koch BCP
    Crit Care; 2020 Sep; 24(1):558. PubMed ID: 32933574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Model-informed precision dosing of beta-lactam antibiotics and ciprofloxacin in critically ill patients: a multicentre randomised clinical trial.
    Ewoldt TMJ; Abdulla A; Rietdijk WJR; Muller AE; de Winter BCM; Hunfeld NGM; Purmer IM; van Vliet P; Wils EJ; Haringman J; Draisma A; Rijpstra TA; Karakus A; Gommers D; Endeman H; Koch BCP
    Intensive Care Med; 2022 Dec; 48(12):1760-1771. PubMed ID: 36350354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of therapeutic drug monitoring of beta-lactam and fluoroquinolones on clinical outcome in critically ill patients: the DOLPHIN trial protocol of a multi-centre randomised controlled trial.
    Abdulla A; Ewoldt TMJ; Hunfeld NGM; Muller AE; Rietdijk WJR; Polinder S; van Gelder T; Endeman H; Koch BCP
    BMC Infect Dis; 2020 Jan; 20(1):57. PubMed ID: 31952493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evaluation of risk factors to predict target concentration non-attainment in critically ill patients prior to empiric β-lactam therapy.
    Imani S; Buscher H; Day R; Gentili S; Jones GRD; Marriott D; Norris R; Sandaradura I
    Eur J Clin Microbiol Infect Dis; 2018 Nov; 37(11):2171-2175. PubMed ID: 30120647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A protocol for a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis: BLING III.
    Lipman J; Brett SJ; De Waele JJ; Cotta MO; Davis JS; Finfer S; Glass P; Knowles S; McGuinness S; Myburgh J; Paterson DL; Peake S; Rajbhandari D; Rhodes A; Roberts JA; Shirwadkar C; Starr T; Taylor C; Billot L; Dulhunty JM
    Crit Care Resusc; 2019 Mar; 21(1):63-68. PubMed ID: 30857514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of β-lactam antibiotic therapeutic drug monitoring on dose adjustments in critically ill patients undergoing continuous renal replacement therapy.
    Economou CJP; Wong G; McWhinney B; Ungerer JPJ; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2017 May; 49(5):589-594. PubMed ID: 28341612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged administration of β-lactam antibiotics - a comprehensive review and critical appraisal.
    Osthoff M; Siegemund M; Balestra G; Abdul-Aziz MH; Roberts JA
    Swiss Med Wkly; 2016; 146():w14368. PubMed ID: 27731492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis.
    Abdul-Aziz MH; Sulaiman H; Mat-Nor MB; Rai V; Wong KK; Hasan MS; Abd Rahman AN; Jamal JA; Wallis SC; Lipman J; Staatz CE; Roberts JA
    Intensive Care Med; 2016 Oct; 42(10):1535-1545. PubMed ID: 26754759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suboptimal Beta-Lactam Therapy in Critically Ill Children: Risk Factors and Outcome.
    Van Der Heggen T; Dhont E; Willems J; Herck I; Delanghe JR; Stove V; Verstraete AG; Vanhaesebrouck S; De Paepe P; De Cock PAJG
    Pediatr Crit Care Med; 2022 Jul; 23(7):e309-e318. PubMed ID: 35426861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of beta-lactam antibiotics in critically ill patients.
    Sulaiman H; Roberts JA; Abdul-Aziz MH
    Farm Hosp; 2022 Mar; 46(3):182-190. PubMed ID: 36183212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of de-escalation of beta-lactam antibiotics on the emergence of antibiotic resistance in ICU patients: a retrospective observational study.
    De Bus L; Denys W; Catteeuw J; Gadeyne B; Vermeulen K; Boelens J; Claeys G; De Waele JJ; Decruyenaere J; Depuydt PO
    Intensive Care Med; 2016 Jun; 42(6):1029-39. PubMed ID: 27025939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of studies on extended versus standard infusion of beta-lactam antibiotics.
    Chen M; Buurma V; Shah M; Fahim G
    Am J Health Syst Pharm; 2019 Sep; 76(18):1383-1394. PubMed ID: 31505562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beta-Lactam Antibiotic Therapeutic Drug Monitoring in Critically Ill Patients: A Systematic Review and Meta-Analysis.
    Pai Mangalore R; Ashok A; Lee SJ; Romero L; Peel TN; Udy AA; Peleg AY
    Clin Infect Dis; 2022 Nov; 75(10):1848-1860. PubMed ID: 35731853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients.
    De Waele JJ; Lipman J; Akova M; Bassetti M; Dimopoulos G; Kaukonen M; Koulenti D; Martin C; Montravers P; Rello J; Rhodes A; Udy AA; Starr T; Wallis SC; Roberts JA
    Intensive Care Med; 2014 Sep; 40(9):1340-51. PubMed ID: 25053248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibiotic Exposure Profiles in Trials Comparing Intensity of Continuous Renal Replacement Therapy.
    Jang SM; Pai MP; Shaw AR; Mueller BA
    Crit Care Med; 2019 Nov; 47(11):e863-e871. PubMed ID: 31397714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience.
    Richter DC; Frey O; Röhr A; Roberts JA; Köberer A; Fuchs T; Papadimas N; Heinzel-Gutenbrunner M; Brenner T; Lichtenstern C; Weigand MA; Brinkmann A
    Infection; 2019 Dec; 47(6):1001-1011. PubMed ID: 31473974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Pharmacokinetics of Beta-Lactam Antibiotics Using Scavenged Samples in Pediatric Intensive Care Patients: The EXPAT Kids Study Protocol.
    Schouwenburg S; Wildschut ED; de Hoog M; Koch BCP; Abdulla A
    Front Pharmacol; 2021; 12():750080. PubMed ID: 34955824
    [No Abstract]   [Full Text] [Related]  

  • 19. Association Between Dexamethasone and Delirium in Critically Ill Patients: A Retrospective Cohort Study of a Large Clinical Database.
    Wu Z; Li H; Liao K; Wang Y
    J Surg Res; 2021 Jul; 263():89-101. PubMed ID: 33639374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study.
    Ehmann L; Zoller M; Minichmayr IK; Scharf C; Maier B; Schmitt MV; Hartung N; Huisinga W; Vogeser M; Frey L; Zander J; Kloft C
    Crit Care; 2017 Oct; 21(1):263. PubMed ID: 29058601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.